Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16322 ↗At a glance
Journal article in British Journal of Pharmacology, 2024. Written by Tessa de Vries and 7 co-authors. Institution: Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Coronary Vessels, Meningeal Arteries, Calcitonin Gene-Related Peptide Receptor Antagonists. Cited 8 times so far (Crossref); 67 references. The full text is freely available (open access, CC BY 4.0). Funded by: Dutch Research Council, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.
Abstract (original language)
Background and Purpose Multiple drugs targeting the calcitonin gene‐related peptide (CGRP) receptor have been developed for migraine treatment. Here, the effect of the monoclonal antibody erenumab on CGRP‐induced vasorelaxation was investigated in human isolated blood vessels, as well as the effect of combining erenumab with the small molecule drugs, namely rimegepant, olcegepant, or sumatriptan. Experimental Approach Concentration–response curves to CGRP, adrenomedullin or pramlintide were constructed in human coronary artery (HCA) and human middle meningeal artery (HMMA) segments, incubated with or without erenumab and/or olcegepant. pA 2 or pK b values were calculated to determine the potency of erenumab in both tissues. To study whether acutely acting antimigraine drugs exerted additional CGRP‐blocking effects on top of erenumab, HCA segments were incubated with a maximally effective concentration of erenumab (3 μM), precontracted with KCl and exposed to CGRP, followed by rimegepant, olcegepant, or sumatriptan in increasing concentrations. Key Results Erenumab shifted the concentration‐response curve to CGRP in both vascular tissues. However, in HCA, the Schild plot slope was significantly smaller than unity, whereas this was not the case in HMMA, indicating different CGRP receptor mechanisms in these tissues. In HCA, rimegepant, olcegepant and sumatriptan exerted additional effects on CGRP on top of a maximal effect of erenumab. Conclusions and Implications Gepants have additional effects on top of erenumab for CGRP‐induced relaxation and could be effective in treating migraine attacks in patients already using erenumab as prophylaxis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Heart Valve Department, ETB-BISLIFE, Beverwijk, The Netherlands.
- Department of Neurosurgery, Erasmus University Medical Center, The Netherlands.
- Novartis Pharma AG, Basel, Switzerland.
- Amgen Inc, Thousand Oaks, California, USA.
ORCID profiles: Tessa de Vries, A H Jan Danser
Funding
- Dutch Research Council
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Cite
APA
de Vries, T., Rubio-Beltrán, E., van den Bogaerdt, A., Dammers, R., Danser, A. H. J., Snellman, J., Bussiere, J., & MaassenVanDenBrink, A. (2024). Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab. British Journal of Pharmacology. https://doi.org/10.1111/bph.16322
Vancouver
de Vries T, Rubio-Beltrán E, van den Bogaerdt A, Dammers R, Danser AHJ, Snellman J, et al. Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab. British Journal of Pharmacology. 2024. doi:10.1111/bph.16322
BibTeX
@article{deVries2024,
author = {de Vries, Tessa and Rubio-Beltrán, Eloísa and van den Bogaerdt, Antoon and Dammers, Ruben and Danser, A H Jan and Snellman, Josefin and Bussiere, Jeanine and MaassenVanDenBrink, Antoinette},
title = {Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16322}
}
EUVIMED